Oral Anticoagulant Therapy in Young Children Utilizing an Extemporaneous Liquid Warfarin Formulation: Evaluation of Anticoagulation Quality, Efficacy, and Safety Outcomes

被引：0
|
作者：
Diamond, Carrie [1 ]
Hennessey, Carole [1 ]
Guerrera, Michael [1 ]
Meldau, Jennifer [1 ]
Guelcher, Christine [1 ]
Diab, Yaser [1 ]
机构：
[1] Childrens Natl Med Ctr, Washington, DC 20010 USA
来源：
PEDIATRIC BLOOD & CANCER | 2017年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
034
引用
收藏
页码：S15 / S16
页数：2
相关论文
共 22 条
  • [21] Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial (vol 20, 49, 2019)
    de Leeuw, Thomas G.
    Mangiarini, Laura
    Lundin, Rebecca
    Kaguelidou, Florentia
    van der Zanden, Tjitske
    Della Pasqua, Oscar
    Tibboel, Dick
    Ceci, Adriana
    de Wildt, Saskia N.
    TRIALS, 2019, 20 (1)
  • [22] A PHASE I-II EVALUATION OF THE SAFETY AND EFFICACY OF THE ORAL HSP90 INHIBITOR DEBIO 0932 IN COMBINATION WITH SOC IN FIRST- AND SECOND-LINE THERAPY OF STAGE IIIB OR IV NSCLC - THE HALO STUDY (HSP90 INHIBITION AND LUNG CANCER OUTCOMES)
    van Ingen, H.
    Purcea, D.
    Brienza, S.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S72 - S72
123